Analytical Data
-
Gene name
UTRN
- Application
-
Alternative Names
UTRN；DMDL；DRP1；Utrophin
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P46939
-
Expression Region
全长
-
AA Sequence
full
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
UTRN, or Utrophin, is a homologue of dystrophin, a protein crucial for muscle function. Mutations in the dystrophin gene lead to Duchenne muscular dystrophy (DMD), a severe genetic disorder characterized by progressive muscle degeneration and weakness. Given utrophin's structural similarities and functional role in stabilizing muscle fibers, researchers have been investigating its potential as a therapeutic target for DMD. The re-expression of utrophin in muscle tissues could compensate for the absence of dystrophin, thereby mitigating the pathology associated with DMD. Studies have focused on the development of utrophin-based therapies, including small compounds that can upregulate utrophin expression and gene therapies aimed at delivering utrophin to affected muscle tissues. Furthermore, understanding the molecular mechanisms governing utrophin’s function and regulation is crucial for designing effective treatments. The research into UTRN recombinant proteins aims not only to explore their therapeutic potential but also to enhance our comprehension of muscle physiology and the pathological mechanisms underlying muscular dystrophies, presenting promising avenues for improving the quality of life for individuals affected by DMD and related disorders.
